Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Telix Pharmaceuticals Limited
  6. Summary
    TLX   AU000000TLX2

TELIX PHARMACEUTICALS LIMITED

(TLX)
  Report
Delayed Australian Stock Exchange  -  12:10:18 2023-02-09 am EST
6.450 AUD   -1.83%
01/18Telix Reports Fourth Quarter 2022 Financial Results
AQ
01/17Energy stocks push Australian shares higher
RE
01/17Transcript : Telix Pharmaceuticals Limited, Q4 2022 Earnings Call, Jan 18, 2023
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Australian Stock Exchange
02/03/2023 02/06/2023 02/07/2023 02/08/2023 02/09/2023 Date
6.78(c) 6.7(c) 6.59(c) 6.57(c) 6.45 Last
683 265 473 724 719 986 308 121 736 792 Volume
-1.45% -1.18% -1.64% -0.30% -1.83% Change
More quotes
Estimated financial data (e)
Sales 2022 156 M 108 M 108 M
Net income 2022 -79,7 M -55,2 M -55,2 M
Net cash position 2022 116 M 80,7 M 80,7 M
P/E ratio 2022 -26,8x
Yield 2022 -
Sales 2023 364 M 252 M 252 M
Net income 2023 17,6 M 12,2 M 12,2 M
Net cash position 2023 111 M 76,9 M 76,9 M
P/E ratio 2023 115x
Yield 2023 -
Capitalization 2 083 M 1 443 M 1 443 M
EV / Sales 2022 12,6x
EV / Sales 2023 5,42x
Nbr of Employees -
Free-Float 73,0%
More Financials
Company
Telix Pharmaceuticals Limited is a radiopharmaceutical company focused on the development of diagnostic and therapeutic radiopharmaceuticals products using Molecularly Targeted Radiation (MTR) to treat cancer. In MTR therapy, a radionuclide is attached to a targeting agent such as a small molecule or antibody. This targeting agent specifically binds to tumors and delivers a radioactive payload in a selective way.... 
Read more
Sector
Biotechnology & Medical Research
Calendar
02/17 | 03:30pmPresentation
More about the company
Ratings of Telix Pharmaceuticals Limited
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about TELIX PHARMACEUTICALS LIMITED
01/18Telix Reports Fourth Quarter 2022 Financial Results
AQ
01/17Energy stocks push Australian shares higher
RE
01/17Transcript : Telix Pharmaceuticals Limited, Q4 2022 Earnings Call, Jan 18, 20..
CI
01/11Transcript : Telix Pharmaceuticals Limited Presents at 41st Annual J.P. Morga..
CI
2022Telix Pharmaceuticals Limited Announces ZIRCON Phase III Renal Cancer Study to be Prese..
CI
2022Telix Pharmaceuticals Appoints Chief Commercial Officer
MT
2022Telix Pharmaceuticals Limited Announces Leadership Changes
CI
2022Telix - First Patient Dosed in Phase II 'IPAX-Linz' Study of TLX101 for Glioblastoma Th..
AQ
2022Telix Pharmaceuticals Limited Announces Illuccix Kit for the Preparation of Gallium Ga ..
CI
2022Telix Pharmaceuticals Limited Announces That First Patient Dosed in Phase II 'IPAX-Linz..
CI
2022Telix Pharmaceuticals Limited agreed to acquire Optimal Tracers from Northern Californi..
CI
2022Telix Pharmaceuticals Acquires Optimal Tracers; Shares Fall 3%
MT
2022Telix Pharmaceuticals Limited Announces Positive Topline Results from Overseas Phase II..
CI
2022Telix Pharmaceuticals Limited Announces Positive Topline Results of ZIRCON Phase III Ki..
CI
2022Telix and UniQuest to Collaborate on Radiolabelled Immune Targeting Peptide
AQ
More news
News in other languages on TELIX PHARMACEUTICALS LIMITED
2022Telix Pharmaceuticals Limited annonce que l'étude de phase III sur le cancer du rein ZI..
2022Telix Pharmaceuticals nomme un directeur commercial
2022Telix Pharmaceuticals Limited annonce des changements de direction
2022Telix Pharmaceuticals Limited annonce la trousse Illuccix pour la préparation du Galliu..
2022Telix Pharmaceuticals Limited annonce que le premier patient a reçu une dose dans l'étu..
More news
ETFs positioned on TELIX PHARMACEUTICALS LIMITEDETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
HAN-GINS Indxx Healthcare Megatrend Equal W...1.04%0.68%-NC
IShares S&P/ASX Small Ordinaries ETF - AUD0.53%-0.65%-Australia
SPDR S&P/ASX Small Ordinaries Fund ETF - AUD0.36%-1.02%-Australia
Vanguard MSCI Australian Small Companies In...0.28%-0.23%-Australia
Vanguard Australian Shares Index ETF - AUD0.09%0.37%-Australia
More ETFs positioned on TELIX PHARMACEUTICALS LIMITED
Chart TELIX PHARMACEUTICALS LIMITED
Duration : Period :
Telix Pharmaceuticals Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TELIX PHARMACEUTICALS LIMITED
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 6,57 AUD
Average target price 9,32 AUD
Spread / Average Target 41,9%
EPS Revisions
Managers and Directors
Christian P. Behrenbruch Group CEO, MD & Executive Director
Darren Smith Group Chief Financial Officer
Harry Kevin McCann Independent Non-Executive Chairman
Colin Hayward Chief Medical Officer
Michael Wheatcroft Chief Scientist
Sector and Competitors
1st jan.Capi. (M$)
TELIX PHARMACEUTICALS LIMITED-9.63%1 443
MODERNA, INC.-8.51%63 136
LONZA GROUP AG23.06%44 913
IQVIA HOLDINGS INC.14.94%43 744
ALNYLAM PHARMACEUTICALS, INC.-7.03%26 789
SEAGEN INC.6.52%25 416